Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Approximately 80% hepatocellular carcinoma (HCC) patients are in intermediate or advanced stages at diagnosis and have lost the chance of curative surgery, resulting in poor prognosis. Lenvatinib was approved in 2018 as a first-line treatment for unresectable HCC. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shijie, Wang, Yiting, Yu, Jiangtao, Wu, Huaxing, Zhou, Yanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688932/
https://www.ncbi.nlm.nih.gov/pubmed/36428618
http://dx.doi.org/10.3390/cancers14225525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688932/
https://www.ncbi.nlm.nih.gov/pubmed/36428618
http://dx.doi.org/10.3390/cancers14225525

Ejemplares similares